{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"216","value":"16.3"},{"groupId":"OG001","lowerLimit":"7","upperLimit":"216","value":"24.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Time to MMR was defined as the time from the date of randomization to the date of the first documented MMR.","dispersionType":"Full Range","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"MEDIAN","populationDescription":"MMR responder set is a subset of FAS and included participants who achieved MMR at any time on randomized treatment. FAS comprised of all randomized participants.","reportingStatus":"POSTED","timeFrame":"216 Weeks","title":"Time to Major Molecular Response (MMR)","type":"SECONDARY","unitOfMeasure":"Weeks"}